SKL PD

Drug Profile

SKL PD

Latest Information Update: 02 Dec 2015

Price : $50

At a glance

  • Originator SK biopharmaceuticals
  • Class Antiparkinsonians
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Parkinson's disease in USA (PO)
  • 04 Jun 2008 Preclinical trials in Parkinson's disease in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top